サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1774923

院内感染診断の世界市場

Hospital Acquired Infections Diagnostics

出版日
ページ情報
英文 469 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
院内感染診断の世界市場
出版日: 2025年07月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 469 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

院内感染診断の世界市場は2030年までに88億米ドルに達する

2024年に83億米ドルと推定される院内感染診断の世界市場は、2024年から2030年にかけてCAGR 1.0%で成長し、2030年には88億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである消耗品は、CAGR 1.3％を記録し、分析期間終了時には58億米ドルに達すると予測されます。機器セグメントの成長率は、分析期間中CAGR 0.5％と推定されます。

米国市場は23億米ドルと推定、中国はCAGR 2.1％で成長予測

米国の院内感染診断市場は、2024年に23億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは2.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.3％と0.9％と予測されています。欧州では、ドイツがCAGR約0.5%で成長すると予測されています。

世界の院内感染診断市場- 主要動向と促進要因のまとめ

現代のヘルスケアシステムで院内感染診断が重要視される理由とは？

院内感染としても知られる病院内感染（HAI）は、世界のヘルスケアシステムに大きな負担を与え続けており、患者の罹患率、入院期間、治療費を押し上げています。カテーテル関連尿路感染症（CAUTI）、中心静脈ライン関連血流感染症（CLABSI）、手術部位感染症（SSI）、人工呼吸器関連肺炎（VAP）などの感染症は、病院全体、特に集中治療室（ICU）で流行しています。抗菌薬耐性（AMR）が世界的にエスカレートする中、HAIのタイムリーな特定と的を絞った治療は、患者の転帰と病院の業績評価指標にとって極めて重要になっています。診断薬は、原因病原体を迅速に検出し、その抗菌薬感受性を判定する最前線の役割を果たし、臨床医が効果的な介入を開始することを可能にすると同時に、広域抗生物質の誤用を最小限に抑えます。規制上の義務付けや償還モデルによって、感染予防・管理（IPC）プロトコルの採用が増加しており、診断の役割は、反応的なものから積極的な感染抑制へと高まっています。病院は認定を維持し、罰則を回避し、ヘルスケア関連コストを削減しなければならないというプレッシャーに直面しており、HAI診断はリスク軽減、アウトブレイクサーベイランス、ケアの質向上において不可欠なツールとして台頭してきています。

診断技術の進歩はHAI検出と臨床対応をどのように加速しているか？

技術革新は、培養ベースの診断から、迅速、ポイントオブケア、そして院内感染のためのマルチプレックス分子ソリューションへの転換を促しています。従来の微生物検査は、病原体を確定的に同定するための基準ではあるが、リアルタイムポリメラーゼ連鎖反応（RT-PCR）、核酸増幅検査（NAAT）、ループ媒介等温増幅法（LAMP）により補完され、多くの場合、より迅速なターンアラウンドのために取って代わられつつあります。これらの分子アッセイは、高い感度と特異性を可能にし、培養に必要な数日間のウィンドウと比較して、しばしば数時間以内に結果を提供します。微生物同定と感受性プロファイリングを統合した自動血液培養システムは、敗血症や血流感染症の診断にますます採用されるようになっています。質量分析プラットフォーム、特にマトリックス支援レーザー脱離イオン化飛行時間法（MALDI-TOF）は、ラボの運用コストを削減しながら、生物同定を加速しています。次世代シーケンサー（NGS）は、感染アウトブレイクを追跡し、耐性遺伝子を特徴付けるための強力なツールとして台頭してきています。さらに、バイオセンサー、マイクロ流体工学、ラボオンチップ技術の進歩により、リアルタイムのデータ出力によるベッドサイド診断が可能になりつつあります。AI主導のアナリティクスと病院全体のサーベイランス・プラットフォームの統合により、感染追跡、予測モデリング、臨床意思決定支援が強化されています。これらの技術革新は、診断のスピードと精度を向上させるだけでなく、早期の隔離と的を絞った治療を促進することで、HAIの蔓延を抑制し、臨床転帰を改善しています。

どのようなヘルスケアのダイナミクスと規制上の圧力が、HAI対策における診断薬導入の触媒となっているか？

多剤耐性菌（MDRO）の増加、侵襲的器具の使用の増加、複雑な合併症を持つ高齢化により、HAIのリスクプロファイルが拡大し、強固な診断能力の必要性が高まっています。病院は、疾病対策予防センター（CDC）、世界保健機関（WHO）、地域保健当局などの規制機関から、HAI発生率を正確かつリアルタイムに監視し報告するよう、ますます厳しく求められています。メディケアおよびメディケイドサービスにおける成果報酬型ヘルスケアモデルとペナルティ構造は、病院に対してHAI発生率を減らすか、あるいは金銭的な影響を受けるリスクを負うかというインセンティブを与えています。合同委員会（Joint Commission）の国家患者安全目標（National Patient Safety Goals）のような認定機関や感染管理基準は、診断コンプライアンスを中核要件として強化しています。COVID-19の大流行は、ヘルスケア環境における交差感染を防ぐための迅速診断の重要性をさらに浮き彫りにしました。ヘルスケア従事者の意識の高まりとIPCトレーニングの実施も、早期発見と抗菌薬スチュワードシップをサポートする統合診断ソリューションへの需要を後押ししています。人手不足と作業負荷の重圧に直面している病院ラボは、ターンアラウンドタイムを維持し、ワークフロー効率を改善するために、自動化と高スループット診断プラットフォームに投資しています。このような動きは、世界中のヘルスケア施設において、診断が感染制御のエコシステムに不可欠な要素になりつつあります。

地域や使用事例を問わず、何が院内感染診断市場の成長を牽引しているのか？

院内感染診断市場の成長は、感染率の上昇、技術革新、進化するヘルスケア説明責任基準の組み合わせによってもたらされます。高所得国では、厳格なサーベイランス要件を満たし、病院の責任を軽減するために、先進的な分子およびデジタル診断プラットフォームに投資しています。新興経済国では、急速な都市化、医療アクセスの拡大、IPCプログラムへの国際的な資金援助により、資源が限られた環境向けに調整された低価格の迅速診断ツールの導入が加速しています。特に腫瘍学、臓器移植、新生児医療では、外科手術、重症治療室、免疫不全患者集団の拡大が、早期かつ正確なHAI診断の需要を高めています。分散型診断、ポイントオブケア検査、在宅医療への動向も、コンパクトで自動化された使いやすい診断ソリューションの新たな応用機会を生み出しています。官民パートナーシップ、有利な償還構造、抗菌薬耐性対策に向けた政府の取り組みが、市場の勢いをさらに加速させています。これらの要因が相まって、市場情勢は、急速に進化する世界の健康状況において、より安全なヘルスケア提供、卓越したオペレーション、感染予防を実現する重要な手段として推進されています。

セグメント

製品（消耗品、機器）、検査（分子検査、従来型検査）、製品タイプ（血液検査、尿検査）、感染（尿路結石、肺炎、手術部位感染、血流感染、その他）

調査対象企業の例

  • Abbott Laboratories
  • Bayer AG
  • Beckman Coulter（a Danaher Company）
  • Becton, Dickinson and Company（BD）
  • bioMerieux
  • Bio-Rad Laboratories, Inc.
  • Cepheid（a Danaher Company）
  • Danaher Corporation
  • Ecolab Inc.
  • F. Hoffmann-La Roche Ltd.
  • GenMark Diagnostics（acquired by Roche）
  • Hologic, Inc.
  • Johnson & Johnson
  • Luminex Corporation
  • Merck KGaA
  • Pfizer Inc.
  • QIAGEN N.V.
  • Siemens Healthineers
  • STERIS plc
  • Thermo Fisher Scientific Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP31442

Global Hospital Acquired Infections Diagnostics Market to Reach US$8.8 Billion by 2030

The global market for Hospital Acquired Infections Diagnostics estimated at US$8.3 Billion in the year 2024, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 1.0% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 1.3% CAGR and reach US$5.8 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 0.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 2.1% CAGR

The Hospital Acquired Infections Diagnostics market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 2.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.3% and 0.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.5% CAGR.

Global Hospital Acquired Infections Diagnostics Market - Key Trends & Drivers Summarized

Why Are Hospital Acquired Infections Diagnostics Becoming a Priority in Modern Healthcare Systems?

Hospital acquired infections (HAIs), also known as nosocomial infections, continue to pose a significant burden on global healthcare systems-driving up patient morbidity, length of stay, and treatment costs. Infections such as catheter-associated urinary tract infections (CAUTIs), central line-associated bloodstream infections (CLABSIs), surgical site infections (SSIs), and ventilator-associated pneumonia (VAP) are prevalent across hospitals, especially in intensive care units (ICUs). As antimicrobial resistance (AMR) escalates globally, timely identification and targeted treatment of HAIs have become critical to patient outcomes and hospital performance metrics. Diagnostics play a frontline role in rapidly detecting the causative pathogens and determining their antimicrobial susceptibility, enabling clinicians to initiate effective interventions while minimizing the misuse of broad-spectrum antibiotics. The rising adoption of infection prevention and control (IPC) protocols, driven by regulatory mandates and reimbursement models, is elevating the role of diagnostics from reactive to proactive infection containment. With hospitals facing increasing pressure to maintain accreditation, avoid penalties, and reduce healthcare-associated costs, HAI diagnostics are emerging as essential tools in risk mitigation, outbreak surveillance, and quality of care improvement.

How Are Advancements in Diagnostic Technologies Accelerating HAI Detection and Clinical Response?

Technological innovations are driving a shift from culture-based diagnostics to rapid, point-of-care, and multiplex molecular solutions for hospital acquired infections. Traditional microbiology, while still a benchmark for definitive pathogen identification, is being complemented-and in many cases replaced-by real-time polymerase chain reaction (RT-PCR), nucleic acid amplification tests (NAATs), and loop-mediated isothermal amplification (LAMP) for faster turnaround. These molecular assays enable high sensitivity and specificity, often delivering results within hours compared to the multi-day window required for cultures. Automated blood culture systems with integrated microbial ID and susceptibility profiling are being increasingly adopted for sepsis and bloodstream infection diagnosis. Mass spectrometry platforms, especially matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF), are accelerating organism identification while reducing lab operational costs. Next-generation sequencing (NGS) is emerging as a powerful tool for tracking infection outbreaks and characterizing resistance genes. Additionally, advancements in biosensors, microfluidics, and lab-on-chip technologies are enabling bedside diagnostics with real-time data output. Integration of AI-driven analytics and hospital-wide surveillance platforms is enhancing infection tracking, predictive modeling, and clinical decision support. These innovations are not only improving diagnostic speed and accuracy but also facilitating early isolation and targeted treatment, thereby curbing HAI spread and improving clinical outcomes.

What Healthcare Dynamics and Regulatory Pressures Are Catalyzing Diagnostic Adoption in HAI Control?

The rising prevalence of multidrug-resistant organisms (MDROs), increased use of invasive devices, and an aging population with complex comorbidities are expanding the risk profile for HAIs, intensifying the need for robust diagnostic capabilities. Hospitals are under growing scrutiny from regulatory bodies such as the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and regional health authorities to monitor and report HAI incidence accurately and in real time. Pay-for-performance healthcare models and penalty structures under Medicare and Medicaid Services are incentivizing hospitals to reduce HAI rates or risk financial consequences. Accreditation agencies and infection control standards such as the Joint Commission’s National Patient Safety Goals are reinforcing diagnostic compliance as a core requirement. The COVID-19 pandemic has further highlighted the importance of rapid diagnostics in preventing cross-infection within healthcare settings. Increased healthcare worker awareness and IPC training are also driving demand for integrated diagnostic solutions that support early detection and antimicrobial stewardship. Hospital labs, facing staffing shortages and workload pressures, are investing in automation and high-throughput diagnostic platforms to maintain turnaround times and improve workflow efficiency. These dynamics are converging to make diagnostics an indispensable component of infection control ecosystems within healthcare institutions globally.

What Is Driving the Growth of the Hospital Acquired Infections Diagnostics Market Across Geographies and Use Cases?

The growth in the hospital acquired infections diagnostics market is driven by a combination of rising infection rates, technological innovation, and evolving healthcare accountability standards. High-income countries are investing in advanced molecular and digital diagnostic platforms to meet stringent surveillance requirements and reduce hospital liability. In emerging economies, rapid urbanization, growing healthcare access, and international funding for IPC programs are accelerating the adoption of low-cost, rapid diagnostic tools tailored for resource-limited settings. The expansion of surgical procedures, critical care units, and immunocompromised patient populations-especially in oncology, organ transplantation, and neonatal care-is fueling demand for early and precise HAI diagnostics. The trend toward decentralized diagnostics, point-of-care testing, and home-based care is also creating new application opportunities for compact, automated, and user-friendly diagnostic solutions. Public-private partnerships, favorable reimbursement structures, and government initiatives aimed at combatting antimicrobial resistance are further driving market momentum. These factors collectively are propelling the hospital acquired infections diagnostics market as a vital enabler of safer healthcare delivery, operational excellence, and infection prevention in a rapidly evolving global health landscape.

SCOPE OF STUDY:

The report analyzes the Hospital Acquired Infections Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Consumables, Instruments); Test (Molecular, Conventional); Type (Blood tests, Urinalysis); Infection (UTI, Pneumonia, Surgical site infection, Bloodstream infections, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Abbott Laboratories
  • Bayer AG
  • Beckman Coulter (a Danaher Company)
  • Becton, Dickinson and Company (BD)
  • bioMerieux
  • Bio-Rad Laboratories, Inc.
  • Cepheid (a Danaher Company)
  • Danaher Corporation
  • Ecolab Inc.
  • F. Hoffmann-La Roche Ltd.
  • GenMark Diagnostics (acquired by Roche)
  • Hologic, Inc.
  • Johnson & Johnson
  • Luminex Corporation
  • Merck KGaA
  • Pfizer Inc.
  • QIAGEN N.V.
  • Siemens Healthineers
  • STERIS plc
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Hospital Acquired Infections Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Hospital-Acquired Infections (HAIs) Accelerates Demand for Diagnostic Solutions
    • Technological Advancements in Molecular Diagnostics Expand Addressable Market for HAI Detection
    • Surge in Antimicrobial Resistance (AMR) Threat Strengthens Business Case for Rapid Diagnostic Tools
    • Integration of Artificial Intelligence and Machine Learning in Diagnostics Drives Innovation in HAI Detection
    • Increased Emphasis on Point-of-Care Testing Solutions for HAIs Expands Market Opportunity
    • Rise in Government Initiatives and Funding for Infection Control Drives Adoption of Diagnostic Technologies
    • Regulatory Pressure on Infection Reporting Systems Expands Market for Automated Diagnostic Tools
    • Growing Demand for Real-Time Diagnostic Results Strengthens Opportunities for Advanced Testing Solutions
    • Expansion of Hospital Infrastructure and Healthcare Facilities Increases Need for Robust Infection Diagnostics
    • Technological Integration With Electronic Health Records (EHR) Drives Demand for Seamless Diagnostic Systems
    • Implementation of Infection Control Protocols in Developing Markets Strengthens Global Market Demand
    • Rising Focus on Reducing Healthcare-Associated Costs Drives Adoption of Cost-Effective Diagnostic Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hospital Acquired Infections Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hospital Acquired Infections Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Hospital Acquired Infections Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Molecular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Molecular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Molecular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Conventional by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Conventional by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Conventional by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Blood tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Blood tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Blood tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Urinalysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Urinalysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Urinalysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Bloodstream infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Bloodstream infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Bloodstream infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for UTI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for UTI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for UTI by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Pneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Pneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Pneumonia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Surgical site infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Surgical site infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Surgical site infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • JAPAN
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • CHINA
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • EUROPE
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Hospital Acquired Infections Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • FRANCE
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 101: France Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • GERMANY
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 137: UK Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Spain 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Spain 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 161: Russia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Russia Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Russia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Russia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Europe Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 200: Australia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Australia Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Australia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Australia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • INDIA
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 212: India Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: India Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: India 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 215: India Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: India 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 218: India Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 224: South Korea Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: South Korea Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: South Korea 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: South Korea 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 248: Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Latin America Historic Review for Hospital Acquired Infections Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 263: Argentina Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Argentina Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Argentina 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Argentina 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 275: Brazil Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Brazil Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Brazil 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Brazil 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 287: Mexico Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Mexico Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Mexico 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Mexico 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Latin America Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 311: Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 312: Middle East Historic Review for Hospital Acquired Infections Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 326: Iran Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Iran Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Iran 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Iran 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 338: Israel Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Israel Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Israel 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Israel 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Saudi Arabia Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Saudi Arabia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 362: UAE Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: UAE Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: UAE 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: UAE 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Middle East Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • AFRICA
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 386: Africa Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Africa Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Africa 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Africa 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030

IV. COMPETITION